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Abstract: Arterial stiffness normally increases with age and has been established as a precursor 
of cardiovascular disease. Interleukin-6 is a pleiotropic inﬂ  ammatory cytokine with an impor-
tant role in the inﬂ  ammatory cascade, such as up-regulation of C-reactive protein (CRP). The 
interleukin-6 –174-G/C promoter polymorphism appears to inﬂ  uence levels of inﬂ  ammatory 
markers, which have been shown to be associated with arterial stiffness. We studied the associa-
tion of this polymorphism with levels of interleukin-6 and CRP and with arterial stiffness. The 
study (n = 3849) was embedded in the Rotterdam Study, a prospective, population-based study. 
Analyses on the association between the –174-G/C polymorphism and pulse wave velocity, 
distensibility coefﬁ  cient, and pulse pressure were performed using analyses of variance. Analyses 
on the levels of inﬂ  ammatory markers and arterial stiffness were performed using linear regres-
sion analyses. Analyses were adjusted for age, sex, mean arterial pressure, heart rate, known 
cardiovascular risk factors, and atherosclerosis. We found pulse wave velocity to be 0.35 m/s 
higher for CC-homozygotes vs. wildtype GG-homozygotes (p = 0.018) with evidence for an 
allele-dose effect (p trend = 0.013), and a similar pattern for pulse pressure (p trend = 0.041). 
No apparent consistent association with the distensibility coefﬁ  cient was found. CRP levels 
were associated with pulse wave velocity (p = 0.007). In conclusion, the interleukin-6 –174 G/C 
polymorphism is associated with increased arterial stiffness and pulse pressure.
Keywords: IL-6, CRP, arterial stiffness, pulse wave velocity, distensibility coefﬁ  cient, pulse 
pressure
Introduction
Arterial stiffness increases with age and has been associated with hypertension, diabetes 
mellitus (DM), end-stage renal disease and atherosclerosis (Avolio et al 1983; Roman 
et al 1992; Girerd et al 1994; London et al 1990; Wada et al 1994; van Popele et al 
2001). Arterial stiffness has recently been established as a predictor of cardiovascular 
events (Benetos et al 1997; Franklin et al 1999; Boutouyrie et al 2002; Mattace-Raso 
et al 2006). The extent of the increase in stiffness may depend on various factors, 
such as genetic variations.
Inﬂ  ammatory markers have been found to be associated with arterial stiffness 
(Mattace-Raso et al 2004; Kullo et al 2005; Tomiyama et al 2005; Vlachopoulos et al 
2005). Further study into variations in genes in the inﬂ  ammatory pathway in relation 
to arterial stiffness may provide more information on potential pathophysiological 
mechanisms. Indeed, signiﬁ  cant heritability estimates have been found for arterial 
stiffness (Sayed-Tabatabaei et al 2005).
Interleukin-6 (IL-6) is a pleiotropic cytokine with many different functions. It 
plays an important role in the acute-phase response and inﬂ  ammatory cascade, such 
as up-regulation of acute-phase proteins as CRP (Castell et al 1990; Heinrich et al 
1990; Nabata et al 1990; Yudkin et al 1999). An association between IL-6 levels and Vascular Health and Risk Management 2008:4(4) 864
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increased arterial stiffness has been described (Diamant et al 
2005; Mahmud and Feely 2005; Vlachopoulos et al 2005). 
Also elevated CRP levels have been shown to be associated 
with increasing pulse pressure and increased arterial stiffness 
(Mattace-Raso et al 2004; Kullo et al 2005; Tomiyama et al 
2005; Vlachopoulos et al 2005). Fishman and colleagues 
(1998) detected a functional polymorphism in the promoter 
region of the human IL-6 gene (G -  C, 174 bp upstream 
from the start site). This polymorphism appears to inﬂ  uence 
the IL-6 gene transcription and is associated with elevated 
CRP levels (Fishman et al 1998; Basso et al 2002; Jenny et al 
2002; Vickers et al 2002; Sie et al 2006).
To the best of our knowledge, the IL-6 gene has not 
been studied in relation to arterial stiffness. We studied the 
association of the IL-6 –174 G/C promoter polymorphism, 
measures of arterial stiffness and levels of CRP and IL-6 
within the Rotterdam Study.
Methods
The Rotterdam Study is an ongoing prospective cohort 
study including 7983 participants of 55 years and older. 
Its general aims are to investigate determinants of chronic 
diseases (Hofman et al 1991). During the ﬁ  rst phase of this 
study (1990–1993), all inhabitants of a Rotterdam suburban 
area (Ommoord) aged 55 years and over were invited to par-
ticipate in this study. The response rate was 78%. The third 
examination phase took place from 1997–1999, during which 
measures of arterial stiffness were performed. Approval of 
the Medical Ethics Committee of the Erasmus University 
Rotterdam was obtained for the Rotterdam Study. From all 
participants written informed consent was acquired. A more 
in depth description of the Rotterdam Study was published 
previously (Hofman et al 1991).
Genotyping
Genomic DNA was extracted from samples of peripheral 
venous blood according to standard procedures. 1–2 ng 
genomic DNA was dispensed into 384-wells plates using 
a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, 
Mountain View, CA, USA). Genotypes were determined 
using Taqman allelic discrimination assay. The Assay-by-
Design service (www.appliedbiosystems.com) was used 
to set up a Taqman allelic discrimination assay for the 
IL-6 –174 G/C polymorphism (Primers: Fw. GACGACCT 
AAGCTGCACTTTTC, Rv. GGGCTGATTGGAAACCT-
TATTAAGATTG. Reporter 1 sequence VIC CTTTAGCAT-
GGCAAGAC and reporter 2 sequence FAM CTTTAGCA 
TCGCAAGAC). The PCR reaction mixture included 2 ng of 
genomic DNA in a 2 μl volume and the following reagents: 
FAM and VIC probes (200 nM), primers (0.9 uM), 2x 
Taqman PCR master mix (ABgene, Epsom, UK). Reagents 
were dispensed in a 384-wells plate using the Deerac Equa-
tor NS808 (Deerac Fluidics, Dublin, Ireland). PCR cycling 
reactions were performed in 384 wells PCR plates in an 
ABI 9700 PCR system (Applied Biosystems Inc., Foster 
City, CA, USA) and consisted of initial denaturation for 
15 minutes at 95 °C, and 40 cycles with denaturation of 15 
seconds at 95 °C and annealing and extension for 60 seconds 
at 60 °C. Results were analyzed by the ABI Taqman 7900HT 
using the sequence detection system 2.22 software (Applied 
Biosystems Inc.). To conﬁ  rm the accuracy of genotyping 
results, randomly selected samples (5% of total sample) 
were re-genotyped using the same method. No inconsisten-
cies were observed.
Measurement of IL-6 and CRP 
plasma levels
Levels of IL-6 and CRP were determined in samples obtained 
at baseline during the ﬁ  rst phase of the Rotterdam Study. The 
methods were described previously (Sie et al 2006).
Arterial stiffness
In this study three measures of arterial stiffness were used: the 
carotid-femoral pulse wave velocity (PWV; or aortic stiffness) 
as a measure of aortic stiffness and the distensibility coefﬁ  cient 
(DC; or carotid stiffness) of the common carotid artery as a 
measure of common carotid arterial stiffness. In addition, pulse 
pressure (PP) was assessed as an indicator of arterial stiffness. 
All measures were obtained on the same day, during the same 
session, during the third follow-up examination.
Carotid-femoral PWV (m/s) was measured using an 
automatic device (Complior, Colson) and was calculated as 
the ratio between the distance travelled by the pulse wave 
and the foot-to-foot time delay.
Common carotid artery distensibility was assessed by 
measuring the vessel wall motion of the right common 
carotid artery using a duplex scanner (ATL Ultramark IV, 
operating frequency 7.5 MHz) connected to a vessel wall 
movement detector system (Hoeks et al 1990; Kool et al 
1994). The cross-sectional arterial wall distensibility coef-
ﬁ  cient (DC) (1/MPa) was calculated as a measure of arte-
rial stiffness. A decreased distensibility coefﬁ  cient implies 
increased carotid stiffness.
Pulse pressure (PP) (mm Hg) was deﬁ  ned as the dif-
ference between systolic and diastolic blood pressure, 
using the mean systolic and diastolic blood pressure of two Vascular Health and Risk Management 2008:4(4) 865
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measurements obtained by measuring blood pressure on the 
right arm using a random-zero sphygmomanometer.
Details on all measures of stiffness, have been described 
previously (van Popele et al 2001; Mattace-Raso et al 2006).
Clinical characteristics
Information on cardiovascular risk factors was collected dur-
ing the third follow-up examination by trained investigators. 
Data on drug use and smoking habits were obtained during the 
home interview. Smoking was classiﬁ  ed as never, former, or 
current smoking. At the research center, measurements were 
performed by skilled personnel using standardized procedures 
and calibrated equipment, as described previously (Hofman 
et al 1991). Blood pressure was measured twice on the right arm 
using a random-zero sphygmomanometer. The average of the 
two blood pressure values was used in the analyses. Length and 
weight were measured and body mass index (BMI) (kg/m2) was 
calculated. Serum total cholesterol and high-density lipoprotein 
(HDL) cholesterol values were determined by an automated 
enzymatic procedure (Boehringer Mannheim System). Diabe-
tes mellitus (DM) was deﬁ  ned as use of antidiabetic medica-
tion and/or a fasting serum glucose level of equal to or above 
7.0 mmol/L (DCDM 1997). Evaluation of the atherosclerotic 
status of participants was accomplished using ultrasonography 
(carotid intima-media thickness [IMT]) and radiography (aortic 
calciﬁ  cation); the methods used, are similar to those that have 
been extensively described previously (Bots et al 1994, 1997; 
Witteman et al 1994; van Popele et al 2001).
Population for analysis
A total of 4024 subjects underwent the physical examination 
of the third phase and PWV was measured in 3550 subjects; 
69 subjects (1.9%) were excluded from the analyses because 
of poor quality of the PWV index recordings, leaving 3481 
subjects (3207 successfully genotyped) whereas common 
carotid distensibility was measured in 3098 subjects (2836 
successfully genotyped). Pulse pressure measurements 
could be determined for all subjects participating in the third 
phase (3833 successfully genotyped). For 2545 genotyped 
subjects, complete data on both PWV, distensibility coefﬁ  -
cient and pulse pressure were available. For 3849 genotyped 
subjects, data were available on one or more measures of 
arterial stiffness. Missing information on measures of arte-
rial stiffness was almost entirely due to logistic reasons.
Statistical analyses
Chi-square tests were performed to test for deviations from 
Hardy-Weinberg equilibrium. Missing data in clinical 
characteristics were imputed using Expectation-Maximization 
algorithms available in SPSS (SPSS Inc., Chicago, IL, USA). 
For serum measurements all values above mean plus three 
times the standard deviation were excluded, as correction 
for outliers. Natural-log transformed (ln-transformation) 
values of IL-6 and CRP levels were used to normalize the 
distribution of these variables. The association between 
genotypes and arterial stiffness was investigated using 
analyses of variance. Analyses on the association of IL-6 
and CRP levels and arterial stiffness were performed using 
linear regression. All analyses were adjusted for age and sex, 
and (if applicable) additionally for mean arterial pressure 
(MAP), heart rate, BMI, HDL and total cholesterol levels, 
smoking, DM. and measures of atherosclerosis (carotid 
IMT and aortic calciﬁ  cation). A p-value of 0.05 and smaller 
was considered signiﬁ  cant in all analyses. The statistical 
analyses were performed using SPSS version 11.0.1 for 
MS-Windows (SPSS Inc.).
Results
General characteristics are described in Table 1 (ln-transformed 
data are back transformed). Genotype and allele proportions 
were in Hardy Weinberg equilibrium (p = 0.18).
The C-allele of the –174 G/C polymorphism (frequency: 
40%) was signiﬁ  cantly associated with an increased PWV, 
with evidence for an allele-dose effect (Figure 1). After 
adjustment for age, gender, MAP, and heart rate, this trend 
was signiﬁ  cant (model 1, p = 0.016), and remained signiﬁ  -
cant after further adjustment for cardiovascular risk factors 
(model 2, p = 0.024), and atherosclerosis (model 3, p = 0.018). 
The association was lost after additional adjustment for levels 
of IL-6 and CRP (data not shown). Those with the CC-geno-
type had a (signiﬁ  cantly) 0.35 m/s higher PWV than those 
with the wildtype GG genotype (model 1, p = 0.013; model 2, 
p = 0.018; model 3, p = 0.013) (Figure 1).
In the analyses of the association of the IL-6 
polymorphism and the carotid distensibility coefﬁ  cient no 
signiﬁ  cant trends (model 1, p = 0.701, model 2, p = 0.579, 
model 3, p = 0.597), or differences between the genotypes 
were found (Figure 1).
The C-allele of the –174 G/C polymorphism, however, 
was signiﬁ  cantly associated with an increased pulse pressure, 
with evidence for an allele-dose effect (Figure 1). After 
adjustment for age and gender this trend was signiﬁ  cant 
(model 1, p = 0.036), and remained signiﬁ  cant after fur-
ther adjustment for cardiovascular risk factors (model 2, 
p = 0.049) and atherosclerosis (model 3, p = 0.041). Those 
with the CC-genotype had a (signiﬁ  cantly) 2.0 mm Hg higher Vascular Health and Risk Management 2008:4(4) 866
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pulse pressure than those with the wildtype GG genotype 
(model 1, p = 0.037; model 2, p = 0.048; model 3, p = 0.041) 
(Figure 1).
The association between the IL-6 –174 G/C polymor-
phism and PWV, the distensibility coefﬁ  cient and pulse pres-
sure was also analyzed in strata of age ( 73 years and  73 
years, with 73 years being the median age). These analyses 
yielded essentially the same ﬁ  ndings as the age-combined 
analyses (data not shown).
After adjustment for age, gender, MAP, and heart 
rate, the level of CRP was signiﬁ  cantly associated with 
PWV (regression coefﬁ  cient [natural log transformed] 
0.208 mg/L, 95% CI 0.119–0.298) (Table 2). This asso-
ciation remained signiﬁ  cant after adjustment for other 
cardiovascular risk factors and measures of atherosclerosis 
(Table 2). An inverse relation of CRP levels and the dis-
tensibility coefﬁ  cient was shown, but was lost after full 
adjustment (Table 2).
Table 1 Population characteristics by IL6 –174 G/C genotype
Characteristic   GG  GC  CC
Total number – No. (%)  1390 (36)  1830 (48)  629 (16)
Age (yrs)    72 ± 7  72 ± 7  73 ± 7
Male sex (%)    42  43  41
BMI (kg/m2)   27  ± 4  27 ± 9  27 ± 4
Systolic blood pressure (mm Hg)  143 ± 21  143 ± 22  144 ± 21
Diastolic blood pressure (mm Hg)  75 ± 11  75 ± 11  75 ± 11
MAP (mm Hg)    106 ± 13  107 ± 13  107 ± 13
Total cholesterol (mmol/l)  5.8 ± 1.0  5.8 ± 1.0  5.8 ± 0.9
HDL-cholesterol (mmol/l)  1.4 ± 0.4  1.4 ± 0.4  1.4 ± 0.4
Smoking (%)  Current  28  32  30
 Former  39  37  38
 Never  33  31  32
Diabetes (%)    8  9  10
IMT (mm)    0.77 ± 0.14  0.78 ± 0.12  0.78 ± 0.14
Aortic calciﬁ  cations (%)a 22  23  20
PWV (m/s)    13.4 ± 2.9  13.5 ± 3.1  13.8 ± 3.2
DC (1/MPa)    10.4 ± 4.2  10.6 ± 4.4  10.1 ± 4.3
PP (mm Hg)    68 ± 17  68 ± 18  69 ± 17
C-reactive protein (mg/L)b,d 2.2  ± 2.3  2.6 ± 2.8  2.5 ± 2.7
Interleukin-6 (pg/mL)c,d 2.1  ± 1.5  2.3 ± 1.7  2.2 ± 1.8
Notes: Continuous values are depicted as mean ± SD; Number based on genotyped subjects with data on either PWV and/or DC and/or PP; aPercentage of subjects with 
aortic calciﬁ  cation over a length of  2.5 cm; bData available for 3556 subjects (n = 1285 [GG], n = 1694 [GC], n = 577 [CC]); cBased on random subgroup (n = 158 [GG], 
n = 212 [GC], n = 63 [CC]); dMeasured in samples obtained during ﬁ  rst phase of Rotterdam Study.
Abbreviations: BMI, body mass index; DC, distensibility coefﬁ  cient; IMT, intima media thickness; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; 
SD, standard deviation.
Figure 1 Association of IL-6 –174 G/C and measures of arterial stiffness.
Notes: Analyses adjusted for age, sex, body mass index, total cholesterol, high density lipoprotein-cholesterol, diabetes mellitus, smoking, and measures of atherosclerosis 
(and for pulse wave velocity and the distensibility coefﬁ  cient for heart rate and mean arterial pressure); Vertical lines depict the 95% conﬁ  dence interval; Pulse wave velocity: 
p for trend 0.018/pulse pressure: p for trend 0.041.
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IL-6 levels, although only available for a small random 
sample (n = 433), were also analyzed. The analyses sug-
gested a tendency towards a positive, although nonsigniﬁ  cant, 
association with PWV, also after adjustment (Table 3). A 
signiﬁ  cant inverse association was found between IL-6 
levels and the distensibility coefficient within model 1 
(Table 3). After full adjustment, this association remained 
near signiﬁ  cant (Table 3).
All analyses stratiﬁ  ed by gender yielded no results essen-
tially different from the overall analyses.
Discussion
We studied a well-known functional polymorphism in the 
promoter region of the Interleukin-6 gene, –174 G/C in rela-
tion to arterial stiffness. The C-allele of the polymorphism 
was signiﬁ  cantly associated with increased PWV and PP. 
CRP levels were signiﬁ  cantly associated with PWV. Findings 
on levels of IL-6 also suggested (although not signiﬁ  cantly) 
a tendency toward an association with arterial stiffness.
The –174 G/C polymorphism is located in the promotor 
of the IL-6 gene and may inﬂ  uence gene-transcription. In 
some studies no effect of this polymorphism on IL-6 and 
CRP levels was found (Nauck et al 2002; Bennet et al 2003; 
Bennermo et al 2004; Lieb et al 2004). However, other stud-
ies describe it as inﬂ  uencing IL-6 and CRP levels (Fishman 
et al 1998; Brull et al 2001; Basso et al 2002; Jenny et al 
2002; Vickers et al 2002; Bruunsgaard et al 2004). Indeed, 
in a previous study in the Rotterdam Study, the C-allele was 
associated with increased CRP levels, but not with IL-6 levels 
(Sie et al 2006). However, we consider an association with 
IL-6 levels biologically plausible, and contribute our (non-
signiﬁ  cant) ﬁ  nding to a very small number of IL-6 samples 
(Sie et al 2006).
Interleukin-6 is a pleiotropic cytokine with many different 
inﬂ  ammatory functions, eg, up-regulation of CRP (Castell 
et al 1990; Heinrich et al 1990; Nabata et al 1990; Yudkin 
et al 1999). IL-6 levels have been associated with arterial 
stiffness. Diamant and colleagues (2005) described a posi-
tive association of IL-6 and CRP levels and increased arte-
rial stiffness in a small Dutch population (n = 32) in both 
type 2 DM patients as well as in healthy controls. Mahmud 
and Feely (2005) described an association of IL-6 and CRP 
levels and PWV in a study of Irish hypertensives (n = 78). 
In a healthy Greek population (n = 100), Vlachopoulos and 
colleagues (2005) also showed IL-6 and CRP levels to be 
correlated with PWV. In a much larger study of 9867 healthy 
Americans, CRP levels were associated with pulse pressure, 
a manifestation of arterial stiffness (Abramson et al 2002). 
Within the Rotterdam Study, an association between CRP 
levels and PWV was shown in 866 subjects, which was 
conﬁ  rmed in our larger sample of 2995 subjects (Mattace-
Raso et al 2004). Further, Kullo and colleagues (2005) found 
a relation between CRP levels and PWV in an American 
population (n = 214).
As CRP and IL-6 levels are associated with arterial stiff-
ness, our ﬁ  ndings of a signiﬁ  cant association of the poly-
morphism and increased PWV is biologically plausible. Our 
signiﬁ  cant ﬁ  ndings for PP are in concordance herewith. We 
found no association between the polymorphism and the dis-
tensibility coefﬁ  cient. PWV and the distensibility coefﬁ  cient 
both reﬂ  ect other anatomical regions (the aorta and carotids, 
respectively), which may contribute to discordances in ﬁ  ndings 
on stiffness. It is also possible, however, that a small effect may 
have gone undetected due to limitations in sample size.
To assess the inﬂ  uence of age on the relation between the 
IL-6 polymorphism and arterial stiffness, we also performed 
Table 2 Association of pulse wave velocity (PWV) and distensibility 
coefﬁ  cient (DC) with levels of C-reactive protein
PWV (n = 2995)  β 95%  CI  p
Model 1  0.208  0.119–0.298   0.001
Model 2  0.159  0.067–0.250  0.001
Model 3  0.124  0.034–0.215  0.007
DC (n = 2634)  β  95% CI  p
Model 1  −0.219  −0.347 – −0.091 0.001
Model 2  −0.098  −0.231 – 0.034  0.147
Model 3  −0.058  −0.191 – 0.074  0.389
Notes: Model 1: adjusted for age, sex, heart rate, and mean arterial pressure; Model 
2: adjusted for age, sex, heart rate, mean arterial pressure, body mass index, total 
cholesterol, high density lipoprotein-cholesterol, diabetes mellitus, and smoking; 
Model 3: adjusted for age, sex, heart rate, mean arterial pressure, body mass index, 
total cholesterol, high density lipoprotein-cholesterol, diabetes mellitus, smoking, and 
measures of atherosclerosis; Presented values are natural-log transformed.
Table 3 Association of pulse wave velocity (PWV) and distensibility 
coefﬁ  cient (DC) with levels of interleukin-6
PWV (n = 316)  β 95%  CI  p
Model 1  0.411  −0.135–0.956 0.139
Model 2  0.259  −0.300–0.818 0.362
Model 3  0.149  −0.402–0.701 0.594
DC (n = 281)  β  95% CI  p
Model 1  −0.696  −1.316 – −0.076 0.028
Model 2  −0.631  −1.281–0.018 0.057
Model 3  −0.593  −1.237–0.051 0.071
Notes: Model 1: adjusted for age, sex, heart rate, and mean arterial pressure; Model 
2: adjusted for age, sex, heart rate, mean arterial pressure, body mass index, total 
cholesterol, high density lipoprotein-cholesterol, diabetes mellitus, smoking; Model 
3: adjusted for age, sex, heart rate, mean arterial pressure, body mass index, total cho-
lesterol, high density lipoprotein-cholesterol, diabetes mellitus, smoking, and measures 
of atherosclerosis; Presented values are natural-log transformed.Vascular Health and Risk Management 2008:4(4) 868
Sie et al
analyses stratiﬁ  ed by age. However, apart from signiﬁ  cance 
(signiﬁ  cance was preserved for PWV in the  73 years group 
and for PP in the  73 years group), the analyses yielded the 
same ﬁ  ndings in the same direction and patterns as in the 
“age-combined” analyses. Therefore, differences in signiﬁ  -
cance may be more likely due to the reduction in group sizes, 
than due to strong age-dependent inﬂ  uence on the relation 
between the IL-6 gene polymorphism and arterial stiffness.
We also found a signiﬁ  cant association of CRP levels 
and PWV. The number of currently available CRP levels 
within the Rotterdam Study was more than three times 
larger than the number available at the time of our previous 
analyses; the results of our present study are in concordance 
with these earlier ﬁ  ndings (Mattace-Raso et al 2004). Our 
ﬁ  ndings suggest IL-6 levels to be positively related to PWV, 
although this association was not signiﬁ  cant. IL-6 has been 
described to be too unstable in time (plasma half-life of less 
than 2 hours) to be precisely measured (Riches et al 1992; 
Waage et al 1989). This might explain the lack of a signiﬁ  -
cant association between PWV and IL-6 levels. In addition 
we have to remark, that the number of subjects with IL-6 
measurements (random sample) was very small.
Our study is based on a large ongoing population-based 
study in a relatively homogeneous population, as 98% of 
the participants in our study are Caucasian and are all living 
in the same suburb of Rotterdam. We adjusted all analyses 
for established cardiovascular risk factors. The distensibility 
coefﬁ  cient has a strong correlation with MAP; a higher MAP 
in the artery stretches the elastin and collagen ﬁ  bres in the 
arterial wall, making the arteries less distensible. Therefore, 
the analyses were adjusted for MAP.
To interpret the ﬁ  ndings correctly, several methodologi-
cal aspects of the measures of arterial stiffness need to be 
discussed. First, pulse waves in the carotid artery and the 
femoral artery travel in opposite directions, while measure-
ments of carotid-femoral PWV is based on the assumption 
that the pulse wave travels from the carotid artery to the 
femoral artery. In this way, measuring the distance between 
the carotid and the femoral artery led to an overestimation of 
the distance between the sites of the pulse waves, resulting 
in overestimation of the velocity of the pulse waves. How-
ever, variations in anatomy are limited and this error may 
be considered similar for all subjects examined, therefore 
we do not think it has seriously biased our results. Second, 
the distance between the carotid and the femoral artery may 
be overestimated in (especially adipose) subjects when this 
distance is measured by tape. To avoid this error we adjusted 
the analyses for BMI. Third, in computing the carotid 
distensibility coefﬁ  cient, we used the brachial PP rather than 
the carotid PP. Information on comparisons between the 
carotid and the brachial PP indicates that the carotid PP is 
lower than the brachial PP but the differences are relatively 
small (Waddell et al 2001).
Some general remarks: data on measures of stiffness 
were not available for all subjects who visited the research 
center. However, missing information was primarily due 
to logistic reasons, which is likely to be random and thus 
will not have biased our results. Second, the cross-sec-
tional design of our study limits the ability to infer a causal 
relationship between the IL-6 –174 G/C polymorphism, 
inﬂ  ammation, and arterial stiffness. Any associations do 
not necessarily imply causality and should be interpreted 
with reservation. Further, we interpreted our results also 
in the context of literature and (known) pathophysiology. 
However, we are also aware that some ﬁ  ndings were not 
signiﬁ  cant and may be chance ﬁ  ndings. Finally, because 
our study was performed in a population of predominantly 
elderly Caucasian subjects, the generalizability of our 
ﬁ  ndings to younger individuals or other ethnicities remains 
uncertain.
In conclusion, the C-allele of the interleukin-6 –174 G/C 
promoter polymorphism is associated with increased PWV 
and PP. Our results consolidate the ﬁ  nding that CRP levels 
are associated with PWV in an elderly Dutch population.
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